Table 2.
Cancer pretreatment
| Pretreatment | n (%) |
|---|---|
| Adjuvant chemotherapy | |
| Anthracycline-containing | 3 (11.5) |
| Taxane- and anthracycline-containing | 10 (38.5) |
| Non-anthracycline and non-taxane: 4 × CMF, 1 × CM | 5 (19.2) |
| None | 8 (30.8) |
| Palliative chemotherapy | |
| Anthracycline-containing | 2 (7.7) |
| Taxane-containing | 1 (3.8) |
| Taxane- and anthracycline-containing | 1 (3.8) |
| Non-anthracycline and non-taxane (4 × capecitabine, 1 × CMF, 2 × vinorelbine) | 7 (26.9) |
| None | 15 (57.7) |
| Adjuvant endocrine therapy | 11 (42.3) |
| Palliative endocrine therapy | 9 (34.6) |
| Palliative radiotherapy | 6 (23.1) |
CMF = Cyclophosphamide, methotrexate and 5-fluorouracil, CM = cyclophosphamide, methotrexate.